List of Excipients in Branded Drug ESTRADIOL VALERATE

Generic Drugs Containing ESTRADIOL VALERATE

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	estradiol valerate	0143-9289	CHLOROBUTANOL
Hikma Pharmaceuticals USA Inc	estradiol valerate	0143-9289	SESAME OIL
Hikma Pharmaceuticals USA Inc	estradiol valerate	0143-9290	BENZYL ALCOHOL
Hikma Pharmaceuticals USA Inc	estradiol valerate	0143-9290	BENZYL BENZOATE

What are the Most Frequently-Used Excipients in ESTRADIOL VALERATE?

# Of NDCs	Excipient
3	BENZYL ALCOHOL
3	BENZYL BENZOATE
3	CASTOR OIL
2	CHLOROBUTANOL

Estradiol Valerate Excipient Strategy and Commercial Opportunities

Last updated: August 27, 2026

Estradiol valerate is an established estrogen prodrug with limited active-ingredient patent protection and stronger commercial potential in formulation, delivery, combination-product, and manufacturing niches. The most attractive opportunities are sterile oil-based injectables, differentiated oral dosage forms, contraceptive combinations, and excipient systems that improve stability, injection tolerability, dose uniformity, or supply-chain resilience.

What dosage forms use estradiol valerate?

Estradiol valerate is used primarily in intramuscular injections and oral tablets. It is hydrolyzed in vivo to estradiol, providing a longer-acting depot effect than unesterified estradiol in an oil vehicle.

Dosage form	Representative product	Typical excipient strategy	Commercial position
Intramuscular injection	Delestrogen and generic equivalents	Vegetable oil vehicle, preservative where applicable, sterile packaging	Generic and contract-manufacturing opportunity
Oral tablet	Estradiol valerate products outside the U.S.; combination products such as Natazia and Qlaira	Lactose or other diluent, starch, povidone, lubricant, coating system	Combination-product and regional-generic opportunity
Oral contraceptive combination	Estradiol valerate/dienogest	Multi-strength tablet matrix, color-coded coating, moisture protection	Higher regulatory and manufacturing complexity
Modified-release oral product	Potential reformulation	Polymer matrix, multiparticulate system, lipid dispersion, enteric protection	Development-stage opportunity
Long-acting injectable	Potential differentiated product	Biodegradable or nonaqueous depot system	Higher technical and regulatory risk

Estradiol valerate is poorly suited to conventional aqueous injection because of its lipophilicity. The established formulation approach uses a nonaqueous oil vehicle. Oral products require control of dissolution, content uniformity, hydrolysis, and impurity formation.

What excipients are most suitable for estradiol valerate injections?

The commercial benchmark is a sterile solution of estradiol valerate in a fixed vegetable oil. Sesame oil is associated with the established Delestrogen presentation and is also widely used for depot steroid injections. Other candidate vehicles include cottonseed oil, castor oil, medium-chain triglycerides, ethyl oleate, and refined pharmaceutical-grade fixed oils.

Injection excipient selection

Excipient or excipient class	Function	Main benefit	Main risk
Sesame oil	Depot vehicle	Established clinical precedent and high lipophilicity compatibility	Allergy concerns, oxidation, viscosity variability
Cottonseed oil	Depot vehicle	Familiar parenteral oil with established supply	Potential regulatory and sourcing limitations
Medium-chain triglycerides	Lower-viscosity vehicle	Improved manufacturability and injection force	May alter depot release and local tolerability
Ethyl oleate	Solubilizing oil	Lower viscosity than many fixed oils	Potential oxidation and extractables concerns
Benzyl alcohol	Preservative in multidose presentations	Supports multidose packaging	Neonatal toxicity concerns and regulatory scrutiny
Nitrogen headspace	Oxidation control	Reduces oxidative degradation	Requires controlled filling and packaging
Light-protective container	Stability protection	Limits photodegradation	Packaging cost and compatibility testing

The preferred development path is a preservative-free single-dose presentation unless a multidose product has a clear commercial advantage. A preservative-free product reduces excipient exposure and simplifies positioning for chronic hormone therapy, but it increases container-closure and sterility requirements.

What technical studies are required for an oil-based injection?

A viable formulation program should evaluate:

1. Solubility of estradiol valerate across temperature ranges.
2. Viscosity and injection force through commercially relevant needles.
3. Particle formation after refrigerated and accelerated storage.
4. Assay, related substances, hydrolysis products, and oxidative impurities.
5. Syringe, vial, stopper, and needle compatibility.
6. Extractables and leachables from elastomers and polymer components.
7. Local tissue tolerability and depot persistence.
8. Sterility assurance and bacterial endotoxin control.
9. In-use stability after vial puncture.
10. Container orientation, shipping stress, and freeze-thaw exposure.

A lower-viscosity formulation can create a meaningful commercial distinction if it permits smaller needles, shorter injection times, or easier administration in outpatient settings. That benefit must be demonstrated in human-factor and usability studies rather than inferred from viscosity data alone.

What excipients are suitable for oral estradiol valerate tablets?

Oral estradiol valerate tablets generally require standard immediate-release excipients. The principal formulation risks are low-dose content uniformity, hydrolysis, moisture sensitivity, dissolution variability, and impurity control.

Core oral excipient platform

A conventional formulation may use:

• Lactose monohydrate or microcrystalline cellulose as a diluent
• Pregelatinized starch or croscarmellose sodium as a disintegrant
• Povidone or hydroxypropyl cellulose as a binder
• Colloidal silicon dioxide as a glidant
• Magnesium stearate or sodium stearyl fumarate as a lubricant
• Hypromellose, titanium dioxide, iron oxides, and polyethylene glycol in the film coating

The choice between lactose and microcrystalline cellulose depends on dose uniformity, compression behavior, moisture control, and compatibility. For very low-dose hormonal tablets, geometric dilution and robust blend segregation controls are more important than simply increasing tablet weight.

A film coat can provide color differentiation, improve swallowability, reduce dusting, and offer limited moisture protection. It should not be described as a stability solution without data because coating permeability and residual moisture can affect degradation.

What formulations are protected by estradiol valerate patents?

The estradiol valerate molecule is old, and its basic composition-of-matter protection is not the principal commercial barrier. Current protection, where it exists, is more likely to involve:

• Specific combinations, particularly estradiol valerate with dienogest.
• Regimens for contraception or menopausal hormone therapy.
• Dose sequencing across multiple tablet strengths.
• Modified-release or depot delivery systems.
• Stabilized formulations.
• Device and packaging configurations.
• Manufacturing processes that improve impurity control or content uniformity.

A formulation patent must be evaluated claim by claim. A patent directed to a broad class of estrogen esters may have limited blocking value if it does not specifically claim estradiol valerate, the relevant excipient range, dosage form, or commercial strength.

How many patents cover estradiol valerate?

There is no meaningful single patent count for estradiol valerate. Patent-family counts vary depending on whether the analysis includes expired composition patents, national-stage applications, formulation claims, method-of-use claims, combination products, and device patents.

For U.S. commercial diligence, the relevant sequence is:

1. Identify the reference listed drug or NDA.
2. Review current Orange Book patent listings.
3. Separate active listings from expired or delisted patents.
4. Map each claim to the proposed product.
5. Check Paragraph IV certifications and litigation records.
6. Review pediatric and regulatory exclusivity separately from patents.

The FDA Orange Book is the controlling commercial reference for listed U.S. drug patents and exclusivity information, not a broad patent-search database (FDA, 2024a).

When does estradiol valerate lose exclusivity?

The active ingredient has no meaningful new-chemical-entity exclusivity remaining. Estradiol valerate products have been marketed for decades, so commercial protection depends on the specific product, approval pathway, formulation, combination, and jurisdiction.

Protection type	Relevance to estradiol valerate
Composition-of-matter patent	Generally expired because the active ingredient is established
NCE exclusivity	Not available for an old active ingredient
Formulation patent	Possible for a specific vehicle, release profile, or stability system
Method-of-use patent	Possible for a defined indication or dosing regimen
Combination-product patent	Relevant to estradiol valerate/dienogest products
Pediatric exclusivity	Product-specific and time-limited
Orphan exclusivity	Generally not central to conventional estradiol valerate products
Regulatory exclusivity	Depends on the applicable NDA and FDA approval history

A generic sponsor should not assume that the absence of active-ingredient protection eliminates all launch barriers. The main residual risks are Orange Book-listed formulation or use patents, product-specific regulatory exclusivity, and manufacturing comparability.

What is the FDA regulatory status of estradiol valerate?

The FDA has approved estradiol valerate products, including injectable estrogen products and combination oral contraceptives. Natazia contains estradiol valerate and dienogest and uses a multi-phase tablet regimen. Its label includes different strengths and inactive ingredients across the tablet sequence, making manufacturing and bioequivalence more complex than for a single-strength tablet (FDA, 2022).

The regulatory pathway depends on the proposed product:

• A therapeutically equivalent injectable referencing an approved estradiol valerate injection may use an ANDA under section 505(j).
• A new delivery system, new route, or materially different formulation may require a 505(b)(2) application.
• A new estradiol valerate combination or indication may require an NDA or 505(b)(2) strategy.
• A contraceptive combination must address both hormonal exposure and regimen-specific efficacy.

For oral products, comparative dissolution and pharmacokinetic performance are central. For depot injections, the formulation itself controls release, so a generic sponsor may face more extensive equivalence and clinical requirements than a conventional immediate-release tablet sponsor.

What is the Orange Book status of estradiol valerate products?

Orange Book analysis must be conducted at the product level. Estradiol valerate may appear as an active ingredient in more than one NDA, while the relevant patents and exclusivity periods attach to the approved product rather than to the molecule in the abstract.

A diligence review should capture:

• NDA number and reference listed drug designation
• Strength and dosage form
• Current marketing status
• Listed patents and expiration dates
• Use codes for method-of-use listings
• Pediatric exclusivity
• Therapeutic-equivalence ratings
• Withdrawal or discontinuation status

A product that is discontinued for commercial reasons can remain relevant as a reference product if it has not been withdrawn for safety or effectiveness reasons. FDA product-status records and the Orange Book must be read together (FDA, 2024a; FDA, 2024b).

Which companies are challenging estradiol valerate products?

The competitive field includes manufacturers of generic injectable esters, global suppliers of oral estradiol valerate combinations, contract manufacturers, and developers of transdermal or long-acting estrogen products.

The most credible generic-entry candidates are companies with:

• Sterile nonaqueous manufacturing capability
• Experience with controlled substances or hormonal products where applicable
• Validated low-dose blending and coating operations
• Access to pharmaceutical-grade fixed oils
• Strong extractables and leachables programs
• Established FDA, EMA, or other major-market regulatory operations

Competition is more likely to arise from manufacturing capability than from a novel active-ingredient platform. Supply reliability, vial capacity, and sterile filling economics can determine market share.

What commercial opportunities exist for excipient suppliers?

1. Low-viscosity injectable vehicles

A validated low-viscosity oil system could support easier administration and lower injection force. The opportunity is strongest if the formulation maintains the established depot exposure and does not require a new clinical development program.

2. Preservative-free multidose alternatives

Single-dose ampoules and prefilled syringes reduce preservative exposure. A multidose system with validated sterility protection could reduce packaging and administration costs, but it faces greater regulatory and microbiological complexity.

3. Oxidation-control systems

Pharmaceutical-grade antioxidants, nitrogen-filled packaging, low-permeability stoppers, and light-protective containers can address oil oxidation. The commercial value depends on measurable shelf-life improvement and reduced impurity growth.

4. Direct-compression and continuous-manufacturing platforms

Oral hormone products are suitable for process-control technologies that improve blend uniformity and reduce segregation. Continuous manufacturing and automated weight control can be commercially valuable for low-dose tablets.

5. Combination-product platforms

Estradiol valerate/dienogest products require reliable production of multiple strengths, colors, and sequential regimens. Suppliers that provide integrated excipient, coating, and process packages can target this segment.

6. Specialty regional products

Many hormone products are marketed differently across the United States, Europe, Latin America, and Asia. Excipient systems that meet multiple pharmacopeial and regulatory requirements can lower reformulation costs for global launches.

How strong is the patent estate for estradiol valerate?

The estate is generally weak at the active-ingredient level and potentially stronger at the product level. Commercial risk should be scored as follows:

Asset category	Patent strength	Commercial implication
Estradiol valerate molecule	Low	Generic entry is theoretically available
Standard oil injection	Low to moderate	Differentiation depends on claims and product-specific listings
Preservative-free presentation	Moderate if narrowly claimed	May support formulation or device protection
Low-viscosity depot system	Moderate to high if clinically differentiated	Can support 505(b)(2) or formulation licensing
Estradiol valerate/dienogest regimen	Moderate to high, product-specific	Combination and regimen claims require detailed review
Novel oral modified release	Potentially high	Requires development evidence and patent drafting
Manufacturing impurity-control process	Moderate	May create trade-secret rather than blocking-patent value

The strongest defensible position is usually a product package combining formulation, device, manufacturing process, and clinical-use claims. A single broad excipient claim is less durable if competitors can substitute an equivalent vehicle.

What generic launch risks exist for estradiol valerate?

Generic launch risk is highest for injectable products when the reference formulation has a narrow composition and the active ingredient has limited aqueous solubility. Key risks include:

• Inability to match depot release with a different oil vehicle
• Injection-site tolerability differences
• Sterility failures during scale-up
• Oxidative impurity formation
• Container-closure incompatibility
• Difficulty demonstrating equivalence for long-acting exposure
• Limited commercial volume relative to sterile manufacturing cost
• Dependence on a single qualified oil supplier

For oral combination products, the major risks are regimen complexity, multiple strengths, color and coating controls, dissolution matching, and patent or use-code exposure.

What licensing deals are commercially attractive?

Licensing value is highest for technologies that solve a measurable product problem:

• A sterile oil vehicle with lower injection force
• A depot system with predictable release
• A validated antioxidant and packaging combination
• A multiparticulate oral system with improved exposure consistency
• A manufacturing process that reduces estradiol valerate degradation
• A combination-product platform that simplifies multi-strength production

A license should distinguish patent rights from know-how. For established actives, manufacturing know-how, regulatory history, analytical methods, and supplier qualification may have more practical value than a broad but weak formulation patent.

Key Takeaways

• Estradiol valerate has limited active-ingredient patent value because the molecule is longstanding.
• The strongest opportunities are formulation, delivery, combination-product, manufacturing, and packaging technologies.
• Sesame-oil-based sterile injections provide the clearest benchmark for parenteral development.
• Lower-viscosity oil vehicles may offer commercial differentiation if injection performance and clinical release are maintained.
• Oral products require strict control of low-dose uniformity, dissolution, moisture, and hydrolysis.
• Estradiol valerate/dienogest products carry greater formulation and regulatory complexity than single-ingredient tablets.
• U.S. patent risk must be assessed through product-specific Orange Book listings and claim charts.
• Generic injectable entry is technically more difficult than standard immediate-release oral entry.
• Excipient suppliers can create value through integrated vehicle, packaging, coating, and manufacturing platforms.
• Trade secrets and process know-how may be more commercially important than broad composition claims.

FAQs

Can estradiol valerate be formulated in water for injection?

Generally, its lipophilicity makes a conventional aqueous solution impractical. Solubilizers, emulsions, nanosuspensions, or alternative delivery systems would require separate development and regulatory justification.

Is sesame oil the only suitable vehicle for estradiol valerate injection?

No. Other pharmaceutical oils may be technically suitable, but each alternative must be evaluated for solubility, viscosity, depot release, oxidation, injection-site tolerability, and regulatory precedent.

Does micronizing estradiol valerate improve an oil injection?

Not necessarily. Micronization is more relevant to suspension systems. A true oil solution requires adequate molecular solubility and physical stability rather than particle-size reduction.

Is a transdermal estradiol valerate product commercially attractive?

It may be attractive as a differentiated delivery system, but transdermal development must address skin permeation, ester conversion, patch or gel stability, dose uniformity, adhesion, and comparative estrogen exposure.

What is the most defensible excipient patent strategy?

The strongest strategy combines a narrowly defined excipient system with measurable performance limits, stability data, manufacturing controls, device claims, and, where supportable, a clinically differentiated dosing profile.

References

1. U.S. Food and Drug Administration. (2022). Natazia prescribing information. FDA.

2. U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Food and Drug Administration. (2024b). Drugs@FDA: FDA-approved drugs database. FDA.

4. National Library of Medicine. (2024). DailyMed: Estradiol valerate injection labeling. U.S. National Library of Medicine.

5. European Medicines Agency. (2023). Qlaira: Product information. EMA.

6. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP.